Cytotoxic Effect of Progesterone, Tamoxifen and Their Combination in Experimental Cell Models of Human Adrenocortical Cancer

Rossini, Elisa; Tamburello, Mariangela; Abate, Andrea; Beretta, Silvia; Fragni, Martina; Cominelli, Manuela; Cosentini, Deborah; Hantel, Constanze; Bono, Federica; Grisanti, Salvatore; Poliani, Pietro Luigi; Tiberio, Guido A M; Memo, Maurizio; Sigala, Sandra; Berruti, Alfredo

Abstract: Progesterone (Pg) and estrogen (E) receptors (PgRs and ERs) are expressed in normal and neoplastic adrenal cortex, but their role is not fully understood. In literature, Pg demonstrated cytotoxic activity on AdrenoCortical Carcinoma (ACC) cells, while tamoxifen is cytotoxic in NCI-H295R cells. Here, we demonstrated that in ACC cell models, ERs were expressed in NCI-H295R cells with a prevalence of ER+ over the ER-. Metastasis-derived MUC-1 and ACC115m cells displayed a very weak ER+/ER- signal, while PgR cells were expressed, although at low level. Accordingly, these latter were resistant to the SERM tamoxifen and scarcely sensitive to Pg, as we observed a lower potency compared to NCI-H295R cells in cytotoxicity (IC50: MUC-1 cells: 67.58 µM (95%CI: 63.22-73.04), ACC115m cells: 51.76 µM (95%CI: 46.45-57.67)) and cell proliferation rate. Exposure of NCI-H295R cells to tamoxifen induced cytotoxicity (IC50: 5.43 µM (95%CI: 5.18-5.69 µM) mainly involving ER+ as their nuclear localization increased after tamoxifen: Δ A.U. treated vs untreated: 12 h: +27.04% (p < 0.01); 24 h: +36.46% (p < 0.0001). This effect involved the SF-1 protein reduction: Pg: -36.34 ± 9.26%; tamoxifen: -46.25 ± 15.68% (p < 0.01). Finally, in a cohort of 36 ACC samples, immunohistochemistry showed undetectable/low level of ERs, while PgR demonstrated a higher expression. In conclusion, ACC experimental cell models expressed PgR and low levels of ER in line with data obtained in patient tissues, thus limiting the possibility of a clinical approach targeting ER. Interestingly, Pg exerted cytotoxicity also in metastatic ACC cells, although with low potency. Keywords: ACC cell lines; ACC primary cells; adrenocortical carcinoma; estrogen receptors; progesterone receptors; tamoxifen.

DOI: https://doi.org/10.3389/fendo.2021.669426
Cytotoxic Effect of Progesterone, Tamoxifen and Their Combination in Experimental Cell Models of Human Adrenocortical Cancer

Elisa Rossini, Mariangela Tamburello, Andrea Abate, Silvia Beretta, Martina Fragni, Manuela Cominelli, Deborah Cosentini, Constanze Hantel, Federica Bono, Salvatore Grisanti, Pietro Luigi Poliani, Guido A. M. Tiberio, Maurizio Memo, Sandra Sigala, and Alfredo Berruti

1 Department of Molecular and Translational Medicine, Section of Pharmacology, University of Brescia at ASST Spedali Civili di Brescia, Brescia, Italy, 2 Pathology Unit, Department of Molecular and Translational Medicine, University of Brescia at ASST Spedali Civili di Brescia, Brescia, Italy, 3 Medical Oncology Unit, Department of Medical and Surgical Specialties, Radiological Sciences, and Public Health, University of Brescia at ASST Spedali Civili di Brescia, Brescia, Italy, 4 Department of Endocrinology, Diabetology and Clinical Nutrition, University Hospital Zurich (USZ) and University of Zurich (UZH), Zurich, Switzerland, 5 Medizinische Klinik und Poliklinik III, University Hospital Carl Gustav Carus Dresden, Dresden, Germany, 6 Surgical Clinic, Department of Clinical and Experimental Sciences, University of Brescia at ASST Spedali Civili di Brescia, Brescia, Italy

Progesterone (Pg) and estrogen (E) receptors (PgRs and ERs) are expressed in normal and neoplastic adrenal cortex, but their role is not fully understood. In literature, Pg demonstrated cytotoxic activity on AdrenoCortical Carcinoma (ACC) cells, while tamoxifen is cytotoxic in NCI-H295R cells. Here, we demonstrated that in ACC cell models, ERs were expressed in NCI-H295R cells with a prevalence of ER-b over the ER-a. Metastasis-derived MUC-1 and ACC115m cells displayed a very weak ER-a/b signal, while PgR cells were expressed, although at low level. Accordingly, these latter were resistant to the SERM tamoxifen and scarcely sensitive to Pg, as we observed a lower potency compared to NCI-H295R cells in cytotoxicity (IC50: MUC-1 cells: 67.58 µM (95%CI: 63.22–73.04), ACC115m cells: 51.76 µM (95%CI: 46.45–57.67) and cell proliferation rate. Exposure of NCI-H295R cells to tamoxifen induced cytotoxicity (IC50: 5.43 µM (95%CI: 5.18–5.69 µM) mainly involving ER-b, as their nuclear localization increased after tamoxifen: ΔA.U. treated vs untreated: 12 h: +27.04% (p < 0.01); 24 h: +36.46% (p < 0.0001). This effect involved the SF-1 protein reduction: Pg: −36.34 ± 9.26%; tamoxifen: −46.25 ± 15.68% (p < 0.01).

Finally, in a cohort of 36 ACC samples, immunohistochemistry showed undetectable/low level of ERs, while PgR demonstrated a higher expression. In conclusion, ACC experimental cell models expressed PgR and low levels of ER in line with data obtained in patient tissues, thus limiting the possibility of a clinical approach targeting ER. Interestingly, Pg exerted cytotoxicity also in metastatic ACC cells, although with low potency.

Keywords: adrenocortical carcinoma, ACC cell lines, ACC primary cells, estrogen receptors, progesterone receptors, tamoxifen
INTRODUCTION

Adrenocortical carcinoma (ACC) is a rare and aggressive tumor with an incidence of 0.7–2 new cases per million populations per year (1). Early diagnosis followed by radical surgical resection associated or not with adjuvant mitotane therapy (2, 3) is the only option that can give to ACC patients a chance of cure (4). The standard systemic treatment for advanced/metastatic ACC patients, not eligible to surgery, is mitotane, which is administered either alone or in combination with Etoposide, Doxorubicin, and Cisplatin (EDP-M regimen) (5). Although some pathological responses have been observed (6), the efficacy of EDP-M is limited and most initially responding patients are destined to relapse and die of the disease. Other cytotoxic therapies administered to patients with disease progression to EDP-M did not show a remarkable activity (7, 8). Molecular target therapies, attempted up to now (9), and immunotherapy (10) appeared ineffective.

Progesterone receptors (PgRs) and estrogen receptors (ERs) are expressed at different intensities in both normal and neoplastic adrenal cortex (11); however, the patho-physiological relevance of the steroid receptor expression in the physiological regulation of adrenal cell proliferation is not yet fully understood. In particular, in adulthood, ER-β is expressed in the glomerular and fasciculated area of the adrenal cortex, while at the prepubertal age, it is mainly located in the reticular area (12, 13). The ER-α subtype appears to be poorly expressed. During the course of neoplastic degeneration, there is an unpredictable rearrangement of the expression of these receptors, and data concerning the expression of the ERs are controversial. Indeed, a negativity for ER-α and an increase of the ER-β in the AdrenoCortical Carcinoma (ACC) have been reported by immunohistochemical analysis (11), while a decrease of ER expression has been observed as the ACC progresses (14, 15). Finally, other studies demonstrated low ER-β levels and/or high levels of ER-α in numerous cases of ACC, leading to an increase in the ER-α/ER-β ratio compared to that observed in healthy tissue (13). In the NCI-H295R cells, it was observed that ER-β gene expression is higher compared to ER-α, and the selective estrogen receptor modulator (SERM) 4-OH-tamoxifen inhibits cell proliferation (16).

The expression of ER subtypes varies in different tissues, although they are often co-expressed (17). The traditional paradigm is that ER-α is oncogenic and increases cell survival, while ER-β exerts an opposite role, being protective and pro-apoptotic. This clear distinction, however, cannot be applied for each tissue and cell expressing both ER subtypes; indeed, ER-α has a dominant role in tissues such as the uterus, mammary glands, pituitary, skeletal muscle, adipose, and bone; whereas, ER-β has a major role in the ovary, prostate, lung, cardiovascular, and central nervous systems (17).

PgR expression was as well detected in ACC (11). Recently, our group demonstrated a cytotoxic effect of Pg in ACC cells (18). Pg treatment of NCI-H295R cells induced apoptosis via activation of PgR with the involvement of both genomic and non-genomic pathways.

In breast cancer cells, PgR is a transcriptional target of ER, and estrogen is well known to be an important stimulator of PgR synthesis (19). Similar results have been obtained in human endometrial carcinoma (20). Interestingly, in a rare and peculiar setting such as pregnancy in ACC patients, in which there are elevated levels of both Pg and E hormones, their role in the control/progression of the disease is controversial. Indeed a study in 12 pregnant ACC patients concluded that pregnancy is associated with shorter survival and disease-free survival compared to control group (21), while another study on 17 treated ACC patients becoming pregnant during the follow-up, the pregnancy seems to be not associated with worse clinical outcome (22). As the authors correctly pointed out, however, pregnancy-associated ACC tended to be discovered at a more advanced stage. Thus, the possibility of a pregnancy-induced more rapid progression cannot be excluded, and we would like to underline that diagnostic and therapeutic delays probably account for the most severe presentation. Tamoxifen and medroxy-progesterone acetate combined treatment exhibited significant inhibitory growth effect on breast cancer (23), endometrial cancer (24), and cisplatin-resistant ovarian cancer cells (25). This combination therapy appeared to be active in phase II studies enrolling endometrial carcinoma patients (26). These data provided the rationale to explore the cytotoxic interaction between selective estrogen receptor modulators (SERMs), such as tamoxifen, and Pg in ACC.

Here, we explored the possible effect of tamoxifen on ACC cell viability and investigated the additive/synergic cytotoxic activity of tamoxifen and progesterone in in vitro ACC experimental cell models.

MATERIALS AND METHODS

Cell Lines

The human NCI-H295R cell line, derived from a primitive ACC in a female patient (27), was obtained from the American Type Culture Collection (ATCC) and cultured as indicated by ATCC. MUC-1 cell line, established form a neck metastasis of an EDP-M treated male patient, was kindly given by Dr. Hantel and cultured as suggested (28). Media and supplements were supplied by Sigma Aldrich Italia, (Milan, Italy).

Primary ACC Cell Culture

Human ACC primary cells were derived from a male patient who underwent surgical removal of metastatic ACC, in progression after EDP-M. The local Ethical Committee approved the project and written informed consent was obtained from the patient. The primary culture ACC115m was obtained as previously described (29) and maintained in MUC-1 medium supplemented with L-Glutamine (2 mM) and amphotericin B (2.5 μg/ml). The clinical characteristics of the patient are reported in Supplemental Table 1. Cells were tested for mycoplasma and authenticated from BMR genomics (Padova, Italy).
### Immunohistochemistry

Tissue samples were obtained from formalin-fixed and paraffin embedded blocks from surgical samples. 2 µm thick sections were used for routine Hematoxylin and Eosin (H&E) staining and immunohistochemistry using the automatic stainer BenchMark ULTRA IHC/ISH System (Ventana). Diagnosis of cortical cell carcinoma was revised according to the most recent WHO criteria (30). The clinical characteristics of the patient are reported in Supplemental Table 1. The following primary antibodies were used: anti-PgR clone 1E2, anti-ER clone SP1. All the primary antibodies were from “ready to use” kits from Ventana. Antigen retrieval was performed for 64 min for PgR and ER at 95°C in Ultra Cell Conditioning Solution (Ultra CC1, Ventana). Signal was revealed using the ultraView Universal DAB Detection kit (Ventana) followed by diaminobenzidine as chromogen and Hematoxylin for nuclear counterstain. Digital images were acquired by an Olympus XC50 camera mounted on a BX51 microscope (Olympus, Tokyo, Japan) using CellFL Imaging software (Soft Imaging System GmbH, Münster, Germany). Expression of PR and ER was semi-quantitatively scored on representative tumor areas based on both percentage [score ranges: 0 (0–5%), 1 (6–29%), 2 (30–69%), 3 (≥70%)] and intensity (score ranges: 0, no expression; 1, weak; 2, moderate; 3, high) of immunoreactive (IR) neoplastic cells.

### Immunofluorescence

Cells were grown onto 12 mm poly-L-lysine coated coverslips for 4 days and were then fixed with paraformaldehyde 4% (w/v) (Immunofox, Bio-Optica, Milan, Italy) for 15 min at 4°C and permeabilized with 20% MetOH and 0.1% Triton X-100 in PBS for 10 min. Non-specific binding was blocked by incubation in PBS containing 0.1% Triton X-100 and 0.2% of BSA for 45 min. Cells were incubated with anti-PgR (raised in rabbit, 1:800, Cell Signaling Technology, Denvers, MA, USA), anti-ER-β (raised in rabbit, 1:500, Abcam, Cambridge, United Kingdom) and anti-ER-α (raised in mouse, 1:500, Invitrogen, Carlsbad, CA, USA) primary antibodies o/n at 4°C. After extensive washes, the anti-rabbit Alexa Fluor 488 (green signal) and anti-mouse Alexa Fluor 555 (red signal) (Immunological Sciences, Rome, Italy) secondary antibodies, and Alexa Fluor 647 Phalloidin (Invitrogen) were applied for 1 h at rt. After rinsing in PBS, coverslips were mounted using DAPI-containing Vectashield mounting medium (Vector Laboratories, Burlingame, CA, USA).

Slides were observed by a LSM 880 Zeiss confocal laser microscope equipped with Plan-Apochromat 63×/1.4 numerical aperture oil objective or by a LSM 510 Zeiss confocal laser microscope (Carl Zeiss AG, Oberkochen, Germany) equipped with Plan-Apochromat 63×/1.4 numerical aperture oil objective. Images were then reconstructed using Zeiss ZEN 2.3 Imaging Software (Carl Zeiss). The specific mean fluorescence intensity of the pixels was quantified using ZEN Black software (Carl Zeiss) and/or ImageJ software (Nation Institute of Health. Bethesda, MD, USA). Several fields, randomly chosen, were acquired and analyzed for each experimental condition.

### Cell Treatments

Cells were treated with increasing concentrations of progesterone (0.1–160 µM; Merck Serono, Milan, Italy) and tamoxifen (0.1–20 µM; Selleckchem Chemicals-DBA Italia, Segrate, Milan, Italy); both drugs were solubilized in DMSO. Preliminary experiments of concentration-response curves were conducted in the ACC cell cultures in order to establish the optimal drug concentration range and length of treatment. All experiments were conducted in charcoal-dextran-treated serum (CTS).

### Measurement of Cell Viability and Proliferation

Cell viability was assessed by 3-(4,5-Dimethyl-2-thiazol)-2,5-diphenyl-2H-tetrazolium bromide (MTT) dye reduction assay as described in Fiorentini et al. (31). Briefly, untreated and drug-treated cells were incubated with MTT dye (at final concentration of 0.5 mg/ml) and solubilized with DMSO. Absorbance was determined at 540/620 nm by a spectrophotometer (GDV, Rome, Italy). Cell proliferation rate was evaluated with TC20 automated cell counter (Bio-Rad Laboratories, Segrate, Milan, Italy). Briefly, cells were grown in 24-well plates, dislodged by trypsinization and suspended in culture medium followed by trypan blue dilution (1:2). The parameter settings were established according to the manufacturer’s instructions. 10 µl of sample was loaded into a slide and counted.

### Drug Combination Experiments

Combination experiments were performed to evaluate the interaction of Pg and tamoxifen on cell viability according to the Chou and Talalay method (32). Cells were treated for 4 days using increasing concentrations of progesterone (7.4–84.3 µM), tamoxifen (0.8–13.5 µM), and mitotane (1.51–17.21 µM) as single drug and in combination, as recommended for the most efficient data analysis (33). The drug concentration curve for the combination has been designed for each ACC cell model based on the respective IC50 of each drug. Data were then converted to Fraction affected (Fa, range from 0 to 1 where Fa = 0 indicating 100% cell viability and Fa = 1 indicating 0% cell viability) and analyzed using the CompuSyn software (CombioSinc. Paramus, NJ, USA) to calculate the Combination Index (CI). A CI value ≤1, = 1, and >1 indicates synergism, additive effect, and antagonism respectively.

### Quantitative RT-PCR

Gene expression was evaluated by q-RT-PCR (ViiA7, Applied Biosystems, Milan, Italy) using SYBR Green as fluorochrome as described elsewhere (34). Sequences of oligonucleotide primers were reported in Supplemental Table 2. Reactions were performed under the following conditions: 1 cycle at 95°C for 10 min, 40 cycles at 95°C for 15 s, 62°C for 1 min. Differences of the threshold cycle (Ct) values between the β actin housekeeping gene and the gene of interest (ΔCt) were then calculated.

### miRNA Analysis

Total RNA, including miRNAs, was extracted from cells using the miRNeasy kit (Qiagen, Milan, Italy), and 1 µg was transcribed into cDNA using miScript II RT kit (Qiagen), following the manufacturer’s protocol. q-RT-PCR was
performed with a miScript System (Qiagen) (35). Reactions were performed under the following conditions: 95°C 15 min; 94°C 15 s, 55°C 30 s, 70°C 30 s, 40 cycles. Sequences of miR-23 used were: miR23a: 5′AUCACAUGCCAGGGAUUCC; miRNA23b: 5′AUCACAUUGCCAGGGAUUACC. Variations in expression of miR-23a/b among different samples were calculated after normalization to U6.  

**Western Blot**

Cells were homogenized in cold RIPA buffer, and total protein concentrations were determined by Bio-Rad Protein Assay (Bio-Rad Laboratories). Proteins (30 µg/lane) were separated by electrophoresis on a 4–12% NuPAGEbis-tris gel system (Life Technologies, Milan, Italy) and electroblotted to a nitrocellulose membrane. Membranes were incubated with an anti-SF1 (0.234 µg/ml; Cell Signaling Technology) and anti-GAPDH (1 µg/ml Merk Millipore, Burlington, MA, USA) primary antibodies according to the manufacturer’s instructions. Secondary HRP-labeled anti-mouse and anti-rabbit antibodies (Santa Cruz Biotechnologies, Heidelberg, Germany) were used, and the specific signal was visualized using a Westar ECL Sun Western blot substrate (Cyanagen, Bologna, Italy). Densitometric analysis of the immunoblots was performed using NIH ImageJ Software.

**Statistical Analysis**

The analysis of the data was carried out by the GraphPad Prism version 5.02 software (GraphPad Software, La Jolla, CA) using the one-way ANOVA with Bonferroni’s multiple comparisons test considering P < 0.05 as threshold for significant difference. IC₅₀ values for each drug were calculated by non-linear regression of the concentration–response curves. All results are expressed as mean ± SEM of three independent experiments, unless otherwise specified. Cytotoxicity experiments were carried out at least three times, each point run in triplicate.  

## RESULTS

**Estrogens in the ACC Cell Models**

Due to the suggested different roles of ER in cell viability, we evaluated whether the ER-α and ER-β subtypes were differentially expressed in ACC experimental cell models. ACC cell lines and the ACC115m primary cell culture were then investigated for ER gene and protein subtype expression. Results on gene expression are reported in **Table 1**, while the mRNA translation into the respective protein was demonstrated by immunofluorescence and reported in **Figure 1** and quantified in **Supplemental Figure 1**. Concerning the ACC cell lines, NCI-H295R cells expressed both ER subtypes, although the gene and the protein both indicated a low level of expression with a prevalence of ER-β over the ER-α (**Figure 1A, Supplemental Figures 1, 2**). Metastasis-derived MUC-1 cell line and ACC115m primary culture, displayed a very weak expression of ER-α and ER-β, both at gene (**Table 1**) and protein levels (**Figure 1**; quantified in the **Supplemental Figure 1**). We would like to underline the peculiar sub-cellular localization of the ER subtypes as we can observe a prevalent nuclear localization of ER-β.

| Target gene | NCI-H295R | MUC-1 | ACC115m |
|-------------|-----------|-------|---------|
| ER-α        | 10.88 ± 0.36 | >15.00 | 11.50 ± 0.83 |
| ER-β        | 9.81 ± 0.38  | >15.00 | 13.43 ± 0.68 |

Values were reported as ΔCt that are differences of the threshold cycle (Ct) values between the β-actin housekeeping gene and the gene of interest (ΔCt), calculated, as described in Materials and Methods.

NCI-H295R cell line expressed the CYP19A1 enzyme (31) and produced 17β-estradiol (10.01 ± 0.77 ng/ml; **Supplemental Methods**). As it has been shown that exogenous administration induced cell growth (16 and unpublished data), to explore the possible involvement of ERs in ACC cytotoxicity and cell proliferation rate, ACC cells were treated with increasing concentrations of tamoxifen for 4 days and then evaluated for cell viability. The ACC cell line NCI-H295R displayed a concentration-dependent cytotoxicity, with the IC₅₀ of 5.43 µM (95% CI: 5.18–5.69 µM) (**Figure 2A**) and the reduction of the cell proliferation rate (**Figure 2B**). MUC-1 cell line and ACC115m primary culture resulted resistant to tamoxifen (**Supplemental Figure 3**), accordingly to the very low ER expression in these ACC cell models. In particular, tamoxifen exposure did not show any effect on cell viability up to 15 µM and then a sharp decrease at 17.5 µM and 20 µM, more evident in ACC115m. Whether this effect is ER-dependent or not needs to be determined.

**Tamoxifen Induced ER-β Nuclear Translocation in NCI-H295R Cell Line**

To evaluate whether the tamoxifen effect involved a selective subtype, NCI-H295R cells were exposed to the drug IC₅₀ and cells were fixed and analyzed at the confocal microscope at different times. **Figure 3A** shows that tamoxifen treatment induced a time-dependent increase of nuclear signal of ER-β, thus suggesting a significant nuclear translocation after 12 h of drug exposure that was maintained up to 24 h (**Figure 3B**), without any modification of the amount and localization of ER-α (**Supplemental Figure 4**). These results suggested that ER-β could be the subtype mainly involved in the tamoxifen effect.

**Pg in the ACC Cell Models**

We already demonstrate that NCI-H295R cells express PgR (31) and that Pg exerts a concentration-dependent cytotoxic effect on NCI-H295R cell lines as well as in ACC primary cell cultures expressing PgR (18). Here, we confirmed this result in other ACC cell models, studying the Pg effect in metastasis-derived cell models, namely MUC-1 cell line and in ACC115m primary cells. We firstly assessed the PgR expression in these cells by q-RT-PCR. The ΔCt obtained was MUC-1: 12.71 ± 0.62; ACC115m: 10.39 ± 0.04 (cDNA belonging from NCI-H295R cells was used as internal positive control: ΔCt: 9.48 ± 0.57), thus suggesting that PgR gene expression was present. Although a direct relationship between mRNA and proteins cannot be established, a correlation between the gene expression and the immunofluorescent signal in these ACC cell models could be observed. Indeed, PgR signal in MUC-1 cells and ACC115m primary cell culture is weaker compared to NCI-H295R cells.
These results are reported in Figure 4 and included NCI-H295R cells as positive control. The immunofluorescence signal quantification is reported in Supplemental Figure 5. A modest cytotoxic effect of both ACC cell models derived from metastatic patients was observed when cells were exposed to increasing Pg concentrations, suggesting that these cells were less sensitive to Pg compared to NCI-H295R cells. Indeed, the IC\textsubscript{50} was 67.58 µM (95% CI: 63.22–73.04 µM) for MUC-1 cells and 51.76 µM (95% CI: 46.45–57.67 µM) for ACC115m cells (Figure 5A). Pg treatment affected as well the cell proliferation rate on each ACC cell model as reported in Figure 5B.

**Effect of Drug Combined Treatment on ACC Cell Viability**

Due to the sensitivity of NCI-H295R cell line to both Pg and tamoxifen, we thus evaluated whether the cytotoxic effect of tamoxifen on NCI-H295R cell viability could be enhanced by Pg, applying the Chou–Talalay method for drug combination experiments (32, 33). Cells were exposed to increasing concentrations of tamoxifen (1.2–13.5 µM) and Pg (7.4–84.3 µM) at 1:6.17 fixed molar ratio for 4 days and then analyzed for cell viability by MTT assay (Figure 6A). The combination index was then calculated, and the analysis revealed a prevalent antagonist effect when the two drugs were combined (Figure 6B). The combination index value for each drug concentration is reported in Supplemental Table 3, and the isobolograms are reported in Supplemental Figure 5.

Finally, since mitotane is the standard treatment for ACC patients, we then evaluated as well the combined treatment NCI-H295R cell line with tamoxifen and mitotane. Results are reported in Supplemental Figure 6, Supplemental Table 4 and showed that the combination has an additive/synergic effect at low concentrations, while, as the drug concentrations increased, the antagonism prevailed.

---

**FIGURE 1 |** ER expression in NCI-H295R, MUC-1 cell lines and ACC115m primary culture. Cells were seeded on poly-L-lysine pre-treated coverslips following by incubation with DAPI for nuclear staining. Panel (A) DAPI; panel (B) phalloidin; panel (C) ER (red signal: ER-α; green signal: ER-β); panel (D) merge. The scale bar of 20 µm is automatically inserted by the software ZEN Black.
Pg and Tamoxifen Reduced SF-1 Expression in NCI-H295R Cells

In order to evaluate the functional effect of Pg and tamoxifen in the NCI-H295R cell line, the effect of these drugs on the expression of the adrenal biomarker, namely SF-1, the pleiotropic transcription factor involved as well in the carcinogenesis (36) was studied. Cells were treated with Pg or tamoxifen at their respective IC$_{50}$ for 4 days and then the SF-1
expression was evaluated. Results are reported in Figure 7. By q-RT-PCR, after Pg and tamoxifen treatment, no differences in the SF-1 gene expression were detected (not shown), while representative western blots were reported in Figure 7.1A. The SF-1 protein expression was modified by both drugs: in particular, as shown in Figure 7.1B, Pg treatment induced a significant SF-1 reduction in NCI-H295R cell line (Pg: $-36.34\% \pm 9.26\%$; tamoxifen: $-46.25\% \pm 15.68\%$; $P < 0.01$).

In order to explain this phenomenon, we investigated the expression of two miRNAs involved in SF-1 regulation, namely miR23a and miR23b (37). The reduction of SF-1 protein expression seemed to be mediated, at least in part, by the increase of miRNA 23a expression, with an increase compared to untreated cells of up to $1.54 \pm 0.11$ in Pg-treated cells and of $1.73 \pm 0.04$ in tamoxifen-treated cells respectively. An increase of miRNA-23b expression was as well observed after tamoxifen treatment ($1.51 \pm 0.02$ compared to untreated cells), while this miRNA did not seem to be involved in the regulation of SF-1 protein expression when NCI-H295R cells are exposed to Pg (Figure 7.1C). SF-1 protein expression after Pg and/or tamoxifen IC$_{50}$ treatment was measured also in MUC-1 cell line, but no significant variations were detected (Figures 7.2A, B).

**PgR and ER Expression in ACC Tissues**

Finally, the expression of ER and PgR was studied by immunohistochemistry in 36 paraffin embedded tumor samples belonging to ACC diagnosed patients. Among this cohort, 13 patients were male and 22 female, with an age median of 53 years (range: 16–79 years), 11 of them were cortisol-secreting, while the others were not secreting. Results...
reported in Table 2 indicated that ERs were absent or present in a very weak expression, while PgR proteins were expressed, although with a variability within the different samples. In particular, concerning the ER positive cells, we could observe that only three ACC samples displayed a percentage of ER moderately positive cells within the range of 30–69%, while 28 ACC displayed less than 5% ER positive cells, with a null or low intensity. Concerning PgR, they presented an evaluable expression in each sample studied, with only three ACC expressing less than 5% of immunoreactive cells. Indeed, almost half of samples expressed between 30 and 69% of immune positive cells and eight samples up to 36 expressed more than 70% of positive cells. A representative example of immunohistochemistry conducted on some ACC tissues is reported in Figure 8. The clinical characteristics are reported in Supplemental Table 1. In detail, ACC29 cells showed a tumor with lobulated morphology, moderate atypia and few mitotic figures. This tumor exhibits focal and moderate PgR expression, scant ER IR-cells, and low proliferation index. ACC32 cells presented an epithelioid morphology with higher nuclear atypia and prominent nucleoli. This tumor has few PgR IR cells with faint staining intensity with no ER expression and moderate proliferation index. ACC55 cells showed a solid growth composed of clusters of eosinophilic cells with frequent nuclear atypia and mitotic figures. Tumor has moderate PgR expression along with moderate expression of ER. Labeling index is higher between these samples, ranging from 15 to 20%.
levels of both ER subtypes and were resistant to tamoxifen. In other experimental cell models such as MUC-1 and ACC115m expressed very weak ER-β, which was demonstrated in endocrine-related cancers.

However, the role of ERs in ACC cell models seemed to be limited to the NCI-H295R cell line, as metastatic derived ACC (at least 40% of PgR+ cells) resulted in a concentration-dependent increase of cytotoxicity (17). Indeed, exposure to Pg of primary cells derived from PgR expressing ACC tissues strongly indicated that they are frequently expressed, with a number of samples displaying a high percentage of immunoreactive cells, although with a large variability among samples. Accordingly, in a recent paper, our group demonstrated that PgR is a protective factor that suppresses uncontrolled proliferation and induces cell differentiation in many tissues and organs, both in physiological condition and in cancer degeneration (17). However, the role of ERs in ACC cell models seemed to be limited to the NCI-H295R cell line, as metastatic derived ACC cell models such as MUC-1 and ACC115m expressed very weak levels of both ER subtypes and were resistant to tamoxifen.

The amount of ER expression in ACC seemed to decrease as disease progresses, at least in our experimental cell models. Indeed, as already underlined, in EDP-M resistant ACC cells, the expression of ER is very low and cells do not respond to the SERM tamoxifen. Accordingly, in our cohort of paraffin-embedded ACC samples, the expression of ER was absent or present in a very weak expression, thus limiting the possibility to explore a clinical approach targeting ER in ACC patients. Another limitation resides in the tamoxifen pharmacokinetic, as the calculated plasma concentration at the steady state after 20 mg tamoxifen for 3 months is about 0.3 µM, that is under the range of concentrations that displayed a cytotoxic effect in our ACC experimental cell models, although tamoxifen presents a distribution volume that is about 50–60 l/kg (39).

Concerning PgR, immunohistochemical analysis of ACC tissues strongly indicated that they are frequently expressed, with a number of samples displaying a high percentage of immunoreactive cells, although with a large variability among samples. Accordingly, in a recent paper, our group demonstrated that exposure to Pg of primary cells derived from PgR expressing ACC (at least 40% of PgR+ cells) resulted in a concentration-dependent increase of cytotoxicity (18) in line with results demonstrating a role this hormone as anti-tumoral drug in different cancers (40–42).

Here, we strengthen the role of PgR in the ACC and the effect of Pg in reducing both cell proliferation and cell viability. This effect seemed to be strictly related to the level of PgR expression, thus the evaluation of the PgR expression during the pathological staging could be of interest, as Pg and its derivative are already part of the cancer supporting care, thus giving the opportunity to have another pharmacological tool over the usual...
systemic therapy. This hypothesis is now under study in a randomized phase II clinical trial.

The cross-talk between ER/PgR was detectable both at physiological and pathological levels in endocrine tissues and tumors (43). About it, it has been suggested that the combined treatment using drugs targeting ER/PgR could be useful, although the safety profile of the drug combination must be considered (43). Thus, as published data support the rationale for a synergism between anti-E and Pg in inducing an antineoplastic effect, we tested the cytotoxic activity of the combination of tamoxifen and Pg also in ACC experimental model of NCI-H295R cells. Results obtained indicated that the tamoxifen/Pg combination did not result in an either additive or synergic effect; rather the resulting effect was of drug antagonism.

We finally investigated the functional effect of tamoxifen and Pg exposure in ACC cell models, and we observed that both drugs are able to decrease the protein expression of the ACC biomarker SF-1, the transcription factor that is a critical regulator of adrenogonadal development and function (44). SF-1, also known as Ad4-binding protein or NR5A1, binds as a monomer to nuclear receptor half sites on DNA (44), and it plays an important role not only in adrenal steroidogenesis but also in cell adhesion, cell proliferation, apoptosis, and angiogenesis of adrenocortical tumor cells (36). Further, Doghman et al. demonstrated that overexpression of SF-1 in NCI-H295R increases proliferation rate (45). Thus, our results on the downregulation of SF-1 protein expression during the cytotoxic effect of tamoxifen and Pg on NCI-H295R cells found their rationale on the pleiotropic role of SF-1. The reduction of SF-1 protein expression along with a not significant modification of SF-1 mRNA expression induced by both drugs, led us to hypothesize that miRNA regulation of transcriptional capability of mRNA could occurred. It is indeed known that miRNAs, by binding to the 3′-untranslated region of target mRNAs, induced translational repression followed by degradation of approximately one-third of human genes (for an extensive review see: 46). Using computational approaches, it is suggested that each miRNA can bind to hundreds of different mRNAs, which collectively results in an extremely fine regulation of protein transcription (46). Thus, the concept that

| code  | PgR intensity | PgR % of IR cells | cumulative | ER intensity | ER % of IR cells | cumulative |
|-------|---------------|--------------------|------------|--------------|-----------------|------------|
| ACC03 | 1             | 2                  | 3          | 0            | 0               | 0          |
| ACC04 | 2             | 3                  | 5          | 1            | 0               | 1          |
| ACC06 | 1             | 1                  | 2          | 2            | 2               | 4          |
| ACC07 | 2             | 3                  | 5          | 2            | 2               | 4          |
| ACC08 | 1             | 2                  | 3          | 0            | 0               | 0          |
| ACC10 | 3             | 3                  | 6          | 2            | 1               | 3          |
| ACC11 | 2             | 2                  | 4          | 0            | 0               | 0          |
| ACC12 | 1             | 1                  | 2          | 1            | 0               | 1          |
| ACC13 | 1             | 2                  | 3          | 0            | 0               | 0          |
| ACC14 | 1             | 2                  | 3          | 1            | 1               | 2          |
| ACC16 | 2             | 2                  | 4          | 1            | 0               | 1          |
| ACC17 | 1             | 0                  | 1          | 0            | 0               | 0          |
| ACC23 | 1             | 0                  | 1          | 0            | 0               | 0          |
| ACC24 | 2             | 2                  | 4          | 0            | 0               | 0          |
| ACC26 | 1             | 2                  | 3          | 0            | 0               | 0          |
| ACC27 | 1             | 2                  | 3          | 1            | 0               | 1          |
| ACC29 | 1             | 2                  | 3          | 1            | 0               | 1          |
| ACC30 | 2             | 3                  | 5          | 0            | 0               | 0          |
| ACC32 | 1             | 1                  | 2          | 0            | 0               | 0          |
| ACC36 | 2             | 2                  | 4          | 1            | 0               | 1          |
| ACC40 | 1             | 1                  | 2          | 0            | 0               | 0          |
| ACC48 | 1             | 2                  | 3          | 2            | 2               | 4          |
| ACC50 | 1             | 2                  | 3          | 1            | 0               | 1          |
| ACC55 | 1             | 2                  | 3          | 0            | 0               | 0          |
| ACC64 | 2             | 3                  | 5          | 0            | 0               | 0          |
| ACC68 | 2             | 3                  | 5          | 0            | 0               | 0          |
| ACC71 | 2             | 2                  | 4          | 1            | 2               | 3          |
| ACC74 | 2             | 2                  | 4          | 0            | 0               | 0          |
| ACC75 | 1             | 1                  | 2          | 0            | 0               | 0          |
| ACC79 | 1             | 0                  | 1          | 0            | 0               | 0          |
| ACC81 | 2             | 2                  | 4          | 0            | 0               | 0          |
| ACC85 | 1             | 3                  | 4          | 0            | 0               | 0          |
| ACC91 | 2             | 3                  | 5          | 1            | 2               | 3          |
| ACC99 | 1             | 2                  | 3          | 0            | 0               | 0          |
| ACC103| 1             | 2                  | 3          | 0            | 0               | 0          |
| ACC115| 1             | 1                  | 2          | 0            | 0               | 0          |
dysregulation of miRNA expression is linked to cancer is now accepted worldwide. Among the cancer-associated miRNAs, miR23a, one of the most studied miRNAs in different types of cancer, has been found to be involved, together with miR23b, in the regulation of SF-1 protein transcription (37). In NCI-H295R cells, we demonstrated that SF-1 reduction could be mediated, at least in part, by the increase of both miR23a and miR23b. The mechanism underlying this inverse correlation between SF-1 protein and miR23a and miR23b expression is still unknown; however, it has been shown that ER-α binding sites are present in the regulatory region of miR23a (47, 48) and miR23b, along with ER-β binding sites in miR23b regulatory region (49). To our knowledge, no evidence of a direct regulation of Pg on miR23a and miR23b is known at the moment; however, an indirect effect of Pg acting on E-ER-miR23a and miR23b regulation could be as well suggested, as it occurs for a large family of miRNAs in breast cancer (50).

Taken together, these results suggest that SF-1 expression seemed to be regulated by ER and PgR. These data, however, are not exhaustive and the full evidence of the inhibitory effect would require the demonstration of a modulation of the expression of other specific β-catenin target genes in NCI-H295R cells by Pg treatment. These further experiments are outside the scope of the present paper and will be a matter of a future study.

**AUTHOR’S NOTE**

Part of these results has been presented at the 19th ENS@T Scientific Meeting—6 Nov 2020 ONLINE and accepted for presentation at the 40th National Meeting of the Italian Society of Pharmacology—9–13 March 2021 Digital Edition.

**DATA AVAILABILITY STATEMENT**

The original contributions presented in the study are included in the article/Supplementary Material. Further inquiries can be directed to the corresponding author.
ETHICS STATEMENT

The studies involving human participants were reviewed and approved by Comitato Etico di Brescia. The patients/participants provided their written informed consent to participate in this study.

AUTHOR CONTRIBUTIONS

Conceptualization, SS, AB, and MF. Methodology, SS, ER, and MT. Formal analysis, AA, E.R, MF, and MC. Investigation, ER, MT, SB, AA, and MC. Writing—original draft preparation, ER, MT, and PP. Writing—review and editing, SS, AB, CH, PP, GT, and MM. Supervision, SS and AB. All authors contributed to the article and approved the submitted version.

REFERENCES

1. Terzolo M, Daffara F, Ardito A, Zaggia B, Basile V, Ferrari L, et al. Management of Adrenal Cancer: A 2013 Update. J Endocrinol Invest (2014) 37(3):207–17. doi: 10.1007/s40618-013-0049-2
2. Terzolo M, Angeli A, Fassnacht M, Daffara F, Tauchmanova L, Conton PA, et al. Adjuvant Mitotane Treatment for Adrenocortical Carcinoma. N Engl J Med (2007) 356(23):2372–80. doi: 10.1056/NEJMoa063360
3. Berruti A, Grisanti S, Pulzer A, Claps M, Daffara F, Loli P, et al. Long-Term Outcomes of Adjuvant Mitotane Therapy in Patients With Radically Resected Adrenocortical Carcinoma. J Clin Endocrinol Metab (2017) 102(4):1358–65. doi: 10.1210/jc.2016-2894
4. Fassnacht M, Assie G, Baudin E, Eisenhofer G, de la Fouchardiere C, Haak HR, et al. Esmo Guidelines Committee. Electronic Address: Clinicalguidelines@Esmo.Org. Adrenocortical Carcinomas and Malignant Phaeochromocytomas: ESOMO-EURACAN Clinical Practice Guidelines for Diagnosis, Treatment and Follow-Up. Ann Oncol (2020) 31(11):1476–90. doi: 10.1016/j.annonc.2020.08.2099
5. Fassnacht M, Terzolo M, Allolio B, Baudin E, Haak H, Berruti A, et al. Firm-Act Study Group. Combination Chemotherapy in Advanced Adrenocortical Carcinoma. N Engl J Med (2012) 66(23):2189–97. doi: 10.1056/NEJMoa1200966
6. Lagana M, Grisanti S, Cosentini D, Ferrari VD, Lazzari B, Ambrosini R, et al. Efficacy of the EDP-M Scheme Plus Adjunctive Surgery in the Management of Patients With Advanced Adrenocortical Carcinoma: The Brescia Experience. Cancers (Basel) (2020) 12(4):941. doi: 10.3390/cancers12040941
7. Cosentini D, Badalamenti G, Grisanti S, Basile V, Rapa I, Cerri S, et al. Activity and Safety of Temozolomide in Advanced Adrenocortical Carcinoma Patients. Eur J Endocrinol (2019) 181(6):681–9. doi: 10.1530/EJE-19-0570
8. Sperone P, Ferrero A, Daffara F, Priola A, Zaggia B, Volante M, et al. Gemcitabine Plus Metronomic 5-Fluorouracil or Capecitabine as a Second-/Third-Line Chemotherapy in Advanced Adrenocortical Carcinoma: A Multicenter Phase II Study. Endocr Relat Cancer (2010) 17(2):445–53. doi: 10.1677/ERC-09-0281
9. Fiorentini C, Grisanti S, Cosentini D, Abate A, Rossini E, Berruti A, et al. Molecular Drivers of Potential Immunotherapy Failure in Adrenocortical Carcinoma. J Oncol (2019) 1:6072863. doi: 10.1155/2019/6072863
10. Grisanti S, Cosentini D, Lagana M, Volta AD, Palumbo C, Massimo Tiberio GA, et al. The Long and Winding Road to Effective Immunotherapy in Patients With Adrenocortical Carcinoma. Future Oncol (2020) 16(36):3017–20. doi: 10.2217/fon-2020-0686
11. de Cremoux P, Rosenberg D, Goussard J, Brémond-Weil C, Tissier F, Tran-Perennou C, et al. Expression of Progesterone and Estradiol Receptors in Normal Adrenal Cortex, Adrenocortical Tumors, and Primary and Nodular Adrenocortical Disease. Endocr Relat Cancer (2008) 15(2):465–74. doi: 10.1677/ERC-07-0081
12. Baquedano MS, Saraco N, Berenzstein E, Pepe C, Bianchini M, Levy E, et al. Identification and Developmental Changes of Aromatase and Estrogen Receptor Expression in Prepubertal and Pubertal Human Adrenal Tissues. J Clin Endocrinol Metab (2007) 92(6):2215–22. doi: 10.1210/jc.2006-2329
13. Barlon L, Magi D, Travies M, Fallo F, Remo A, et al. Expression of Aromatase and Estrogen Receptors in Human Adrenocortical Tumors. Virchows Arch (2008) 452(2):181–91. doi: 10.1007/s00420-007-0542-0
14. Medvid S, Guan H, Yang K. Bishopenol A Stimulates Adrenal Cortical Cell Proliferation Via Erp-Mediated Activation of the Sonic Hedgehog Signalling Pathway. J Steroid Biochem Mol Biol (2018) 178:254–62. doi: 10.1016/j.jsbmb.2018.01.004
15. Shen XC, Gu XC, Qiu YQ, Du CJ Fu YB, Wu J. Estrogen Receptor Expression in Adrenocortical Carcinoma. J Zhejiang Univ Sci B (2009) 10(1):1–6. doi: 10.1631/jzus.B0802072
16. Montanaro D, Maggioni M, Recchia AG, Siranni R, Aquila S, Barzon L, et al. Antiestrogens Upregulate Estrogen Receptor Beta Expression and Inhibit Adrenocortical H295R Cell Proliferation. J Mol Endocrinol (2005) 35(2):245–56. doi: 10.1677/jme.1.01806
17. Zhao C, Dahlman-Wright K, Gustafsson J-A. Estrogen Receptor & An Overview and Update. Nucl Recept Signal (2008) 6:003. doi: 10.1621/ nrrs.06003
18. Fragni M, Fiorentini C, Rossini E, Fisogni S, Vezzoli S, Bonini SA, et al. In Vitro Antitumor Activity of Progesterone in Human Adrenocortical Carcinoma. Endocrine (2019a) 63(3):592–601. doi: 10.1007/s12020-018-1795-x
19. Katzenellenbogen BS, Norman MJ. Multihormonal Regulation of the Progesterone Receptor in MCF-7 Human Breast Cancer Cells: Interrelationships Among Insulin/Insulin-Like Growth factor-I, Serum, and Estrogen. Endocrinology (1990) 126(2):891–8. doi: 10.1210/endo-126-2-891
20. Carlson JA, Allegra JC, Day TG Jr, Wittliff JL. Tamoxifen and Endometrial Neoplasia. J Clin Endocrinol Metab (2017) 102(4):1358–65. doi: 10.1210/endo-2016-1795
21. Abiven-Lepage G, Coste J, Tissier F, Groussin L, Billaud L, Douset B, et al. Adrenocortical Carcinoma and Pregnancy: Clinical and Biological Features and Prognosis. Eur J Endocrinol (2010) 163(5):793–800. doi: 10.1530/EJE-10-0412
22. de Corbière P, Ritzel K, Kazabat L, Ropers M, Schott M, Libe R, et al. Pregnancy in Women Previously Treated for an Adrenocortical Carcinoma. J Clin Endocrinol Metab (2015) 100(12):4604–11. doi: 10.1210/jc.2015-2341
23. Altomina MA, Bilir A, Gedikoglu G, Ozcan E, Oktem G, Kaplanuloglu M. Medroxyprogesterone and Tamoxifen Augment Anti-Proliferative Effect and Reduce Mitochondria-Toxicity of Epirubicin in FM3A Tumor Cells In Vitro. Cell Biol Int (2007) 31(5):473–81. doi: 10.1016/j.cellbi.2006.11.013
24. Zaino RJ, Satyaswaroop PG, Mortel R. Hormonal Therapy of Human Adrenocortical Carcinoma in a Nude Mouse Model. Cancer Res (1985) 45(2):539–41.
25. Wen L, Hong D, Yanjin W, Mingyue Z, Baohua L. Effect of Tamoxifen, Methoxyprogesterone Acetate and Combined Treatment on Cellular
Proliferation and Apoptosis in SKOV3/DDP Cells Via the Regulation of Vascular Endothelial Growth Factor. Arch Gynecol Obstet (2013) 287(5):997–1004. doi: 10.1007/s00404-012-2656-x

26. Herzog TJ. What is the Clinical Value of Adding Tamoxifen to Progestins in the Treatment [Correction for Treatment] of Advanced or Recurrent Endometrial Cancer? Gynecol Oncol (2004) 92(1):1–3. doi: 10.1016/j.ygyno.2003.11.014

27. Rainey WE, Saner K, Schimmer BP. Adrenocortical Cell Lines. Mol Cell Endocrinol (2004) 228(1-2):23–38. doi: 10.1016/j.mce.2003.12.020

28. Hantel, Shaprio I, Poli G, Chiapponi C, Bidingmaier M, Reincke M, et al. Targeting Heterogeneity of Adrenocortical Carcinoma: Evaluation and Extension of Preclinical Tumor Models to Improve Clinical Translation. Oncotarget (2016) 7(48):79292–304. doi: 10.18632/oncotarget.12685

29. Frangi M, Palmia Lopez LP, Rossini E, Abate A, Cosentini D, Salvi V, et al. In Vitro Cytotoxicity of Cabazitaxel in Adrenocortical Carcinoma Cell Lines and Human Adrenocortical Carcinoma Primary Cell Cultures. Mol Cell Endocrinol (2019b) 498:110585. doi: 10.1016/j.mce.2019.110585

30. Lloyd RV, Osamura RY, Klöppel G, Rosai J. Antisecretive and Antitumor Activity of Abiraterone Acetate in Human Adrenocortical Carcinoma Primary Cell Cultures. Mol Cell Endocrinol (2019b) 498:110585. doi: 10.1016/j.mce.2019.110585

31. Fiorentini C, Fragni M, Perego P, Stabile A, Bodei S, Cristinelli L, Simeone C, et al. Increased Steroidogenic Factor-1 Dosage Triggers Adrenocortical Cell Proliferation and Cancer. Mol. Endocrinol (2007) 12:2968–87. doi: 10.1210/me.2007-0120

32. Hantel, Shapiro I, Poli G, Chiapponi C, Bidingmaier M, Reincke M, et al. Targeting Heterogeneity of Adrenocortical Carcinoma: Evaluation and Extension of Preclinical Tumor Models to Improve Clinical Translation. Oncotarget (2016) 7(48):79292–304. doi: 10.18632/oncotarget.12685

33. Chou TC. Theoretical Basis, Experimental Design, and Computerized Simulation of Synergism and Antagonism in Drug Combination Studies. Pharmacol Rev (2006) 58(3):621–81. doi: 10.1124/pr.58.3.10

34. Frangi C, Bonini SA, Bodei S, Cristinelli L, Simeone C, et al. Inhibition of Survivin is Associated With Zoledronic Acid-Induced Apoptosis of Prostate Cancer Cells. Anticancer Res (2016a) 36:913–20.

35. Frangi M, Bonini SA, Bettinolli P, Bodei S, Generali D, Bottini A, et al. The miR-21/PTEN/Akt Signaling Pathway is Involved in the Anti-Tumoral Effects of Zoledronic Acid in Human Breast Cancer Cell Lines. Naunyn Schmiedebergs Arch Pharmacol (2016b) 389(5):529–38. doi: 10.1007/s00210-016-1224-8

36. Lalli E, Doghman M, Latre de Late P, El Wakil A, Mus-Veteau I. Beyond the Treatment [Correction for Treatment] of Advanced or Recurrent Endometrial Cancer? Gynecol Oncol (2004) 92(1):1–3. doi: 10.1016/j.ygyno.2003.11.014

37. Shen L, Yang S, Huang W, Xu W, Wang Q, Song Y, et al. MicroRNA23a and microRNA23b Deregulation Derepresses SF-1 and Upregulates Estrogen Signaling in Ovarian Endometriosis. J Clin Endocrinol Metab (2013) 98 (4):1573–82. doi: 10.1210/jc.2012-3010

38. Gruberger-Saal SK, Bendahl PO, Saal LH, Laakso M, Hegardt C, Eden P, et al. Estrogen Receptor Beta Expression is Associated With Tamoxifen Response in ERalpha-negative Breast Carcinoma. Clin Cancer Res (2007) 13 (7):1987–94. doi: 10.1128/1078-0432.CCR-06-1823

39. Tamoxifen. Ibm Micromedex.® DRUGDEX® (Electronic Version) - Greenwood Village, Colorado, USA: IBM Watson Health. Available at: https://www.micromedexsolutions.com/ (Accessed January, 04, 2021).

40. Boonyaratanakornkit V, McGowan E, Sherman L, Mancini MA, Cheskis BJ, Edwards DP. The Role of Extraneural Signaling Actions of Progesterone Receptor in Mediating Progesterone Regulation of Gene Expression and the Cell Cycle. Mol Endocrinol (2007) 21:359–75. doi: 10.1210/me.2006-0337

41. Altinho MA, Ozpinar A, Elmaci I. Reproductive Epidemiology of Glial Tumors may Reveal Novel Treatments: High-Dose Progestins or Progesterone Antagonists as Endocrine-Immune Modifiers Against Glioma. Neurosurg Rev (2019) 42(2):351–69. doi: 10.1007/s10143-018-0953-1

42. Motamed HR, Shariati M, Ahmadi R, Khatamsaz S, Mokhtari M. The Apoptotic Effects of Progesterone on Breast Cancer (MCF-7) and Human Osteosarcoma (MG-63) Cells. Physiol Int (2020) 107(3):406–18. doi: 10.1556/2606.2020.00034

43. Truong TH, Lange CA. Deciphering Steroid Receptor Crosstalk in Hormone-Driven Cancers. Endocrinology (2018) 159(12):3897–907. doi: 10.1210/en.2018-00831

44. Lalli E. Adrenocortical Development and Cancer: Focus on SF-1. J Mol Endocrinol (2010) 44(6):301–7. doi: 10.1677/JME-09-0143

45. Doghman M, Karpova T, Rodrigues GA, Arhatte M, De Moura J, Cavalli LR, et al. Increased Steroidogenic Factor-1 Dosage Triggers Adrenocortical Cell Proliferation and Cancer. Mol. Endocrinol (2007) 12:2968–87. doi: 10.1210/me.2007-0120

46. Jonas S, Izaurrelde E. Towards a Molecular Understanding of MicroRNA-Mediated Gene Silencing. Nat Rev Genet (2015) 16(7):421–33. doi: 10.1038/nrg3985

47. Bhut-Kasabhati P, Wang G, Collins NR, Thomson MJ, Geistlinger TR, Carroll JS, et al. Estradiol-Regulated microRNAs Control Estradiol Response in Breast Cancer Cells. Nucleic Acids Res (2009) 37(14):4850–61. doi: 10.1093/nar/gkp500

48. Huang FY, Wong DK, Seto WK, Lai CL, Yuen MF. Estradiol Induces Apoptosis Via Activation of miRNA-23a and p53: Implication for Gender Difference in Liver Cancer Development. Oncotarget (2015) 6(33):34941–52. doi: 10.18632/oncotarget.5472

49. Paris O, Ferraro I, Grober OM, Ravo M, De Filippo MR, Giurato G, et al. Inhibition of Survivin is Associated With Zoledronic Acid-Induced Apoptosis of Prostate Cancer Cells. Anticancer Res (2016a) 36:913–20.

50. McFall T, McKnight B, Rosati R, Kim S, Huang Y, Viola-Villegas N, et al. Apoptotic Effects of Progesterone on Breast Cancer (MCF-7) and Human Osteosarcoma (MG-63) Cells. Physiol Int (2020) 107(3):406–18. doi: 10.1556/2606.2020.00034

51. Altinho MA, Ozpinar A, Elmaci I. Reproductive Epidemiology of Glial Tumors may Reveal Novel Treatments: High-Dose Progestins or Progesterone Antagonists as Endocrine-Immune Modifiers Against Glioma. Neurosurg Rev (2019) 42(2):351–69. doi: 10.1007/s10143-018-0953-1

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2021 Rossini, Tamburella, Abate, Beretta, Frangi, Cominelli, Cosentini, Hantel, Bono, Grisanti, Poliani, Tiberio, Memo, Sigala and Berruti. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.